VERA
Vera Therapeutics, Inc. [VERA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
VERA Stock Summary
Top 10 Correlated Stocks
VERA
In the News
VERA Financial details
Company Rating
-
Market Cap
2.63B
Income
-95.68M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
51
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-8.33
Forward P/E
-
PEG
2.61
P/S
-
P/B
6.9
P/C
-
P/FCF
-9.69
Quick Ratio
6.5
Current Ratio
6.97
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.28
EPS next Y
-
EPS next Q
-
EPS this Y
-32.84%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
28.89%
-
-
-
-
SMA20
-5%
SMA50
-11.63%
SMA100
-5%
Inst Own
-
Inst Trans
-
ROA
-58%
ROE
-82%
ROC
-0.72%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
6.05-50.78
52W High
-28.04%
52W Low
+499.67%
RSI
33
Rel Volume
0.43
Avg Volume
1.38M
Volume
599.08K
Perf Week
-6.28%
Perf Month
-11.23%
Perf Quarter
48.74%
Perf Half Y
23.13%
-
-
-
-
Beta
1.049
-
-
Volatility
0.53%, 2.25%
Prev Close
-3.05%
Price
35.98
Change
-4.44%
Company Profile
- Volume Average 1.38M
- Market Capitalization 2.63B
- Employee 51
- CEO Dr. Marshall W. Fordyce M.D.
- Headquarters Brisbane,CA,US
- IPO Date 2021-05-14
-
Website
https://veratx.com 
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
